<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Appl Oral Sci</journal-id>
      <journal-id journal-id-type="iso-abbrev">J Appl Oral Sci</journal-id>
      <journal-id journal-id-type="publisher-id">J. Appl. Oral. Sci.</journal-id>
      <journal-title-group>
        <journal-title>Journal of Applied Oral Science</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1678-7757</issn>
      <issn pub-type="epub">1678-7765</issn>
      <publisher>
        <publisher-name>Faculdade de Odontologia de Bauru da Universidade de S&#xE3;o
Paulo</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24212997</article-id>
      <article-id pub-id-type="pmc">3881846</article-id>
      <article-id pub-id-type="doi">10.1590/1679-775720130148</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Mandibular metastasis of adenocarcinoma from prostate cancer: case report
according to epidemiology and current therapeutical trends of the advanced prostate
cancer</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>de MENEZES</surname>
            <given-names>Juliana Dreyer da Silva</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>CAPPELLARI</surname>
            <given-names>Pietro Franchon Marques</given-names>
          </name>
          <xref ref-type="aff" rid="aff02">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>CAPELARI</surname>
            <given-names>Marcos Maur&#xED;cio</given-names>
          </name>
          <xref ref-type="aff" rid="aff03">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>GON&#xC7;ALVES</surname>
            <given-names>Paulo Zupelari</given-names>
          </name>
          <xref ref-type="aff" rid="aff04">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>TOLEDO</surname>
            <given-names>Gustavo Lopes</given-names>
          </name>
          <xref ref-type="aff" rid="aff05">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>TOLEDO FILHO</surname>
            <given-names>Jo&#xE3;o Lopes</given-names>
          </name>
          <xref ref-type="aff" rid="aff06">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>SALES-PERES</surname>
            <given-names>Arsenio</given-names>
          </name>
          <xref ref-type="aff" rid="aff07">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>MARZOLA</surname>
            <given-names>Cl&#xF3;vis</given-names>
          </name>
          <xref ref-type="aff" rid="aff08">8</xref>
        </contrib>
      </contrib-group>
      <aff id="aff01"><label>1</label>Hospital for Rehabilitation of Craniofacial Anomalies, Bauru, SP,
Brazil.</aff>
      <aff id="aff02"><label>2</label>Santa Casa de Miseric&#xF3;rdia Hospital, Ribeir&#xE3;o Preto, SP , Brazil.</aff>
      <aff id="aff03"><label>3</label>Department of Community Health, School of Oral and Maxillofacial
Traumatology, Regional APCD, Bauru, SP, Brazil.</aff>
      <aff id="aff04"><label>4</label>Bauru Base Hospital Association, Bauru, SP, Brazil.</aff>
      <aff id="aff05"><label>5</label>Department of Biological Sciences, Bauru School of Dentistry, University
of S&#xE3;o Paulo; School of Oral and Maxillofacial Traumatology, Regional APCD, Bauru, SP,
Brazil.</aff>
      <aff id="aff06"><label>6</label>Department of Biological Sciences, Bauru School of Dentistry, University
of S&#xE3;o Paulo; School of Oral and Maxillofacial Traumatology, Regional APCD, Bauru Base
Hospital Association, Bauru, SP, Brazil.</aff>
      <aff id="aff07"><label>7</label>Department of Pediatric Dentistry, Orthodontics and Community Health,
Bauru School of Dentistry, University of S&#xE3;o Paulo, Bauru, SP, Brazil.</aff>
      <aff id="aff08"><label>8</label>Bauru School of Dentistry, University of S&#xE3;o Paulo; School of Oral and
Maxillofacial Traumatology, Regional APCD, Bauru, SP, Brazil.</aff>
      <author-notes>
        <corresp id="c01"><bold>Corresponding address:</bold> Juliana Dreyer da Silva de Menezes - Rua Aviador
Gomes Ribeiro. 12-47/302 - Vila Noemy - Bauru - SP - Brasil - 17014-000 - Phone: 55
14 81265110 / 55 14 31043544 - e-mail: <email>dreyer.ju@gmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Sep-Oct</season>
        <year>2013</year>
      </pub-date>
      <volume>21</volume>
      <issue>5</issue>
      <fpage>490</fpage>
      <lpage>495</lpage>
      <history>
        <date date-type="received">
          <day>05</day>
          <month>2</month>
          <year>2013</year>
        </date>
        <date date-type="rev-recd">
          <day>24</day>
          <month>5</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>04</day>
          <month>6</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited. </license-p>
        </license>
      </permissions>
      <abstract>
        <p>Prostate cancer represents the most frequent non-cutaneous neoplasia in males. This
type of neoplasia can develop peculiar patterns of evolution, presenting, in many
cases, precocious relapses and metastasis. Bone metastasis in the mouth is extremely
rare, and represents 1% of all malignant mouth neoplasias. The aim of the present
study is to report a clinical case of bone metastasis in the mandibular region
associated with a tumoral prostate adenocarcinoma, as well as to discuss connected
aspects about diagnosis, prognosis and integrated treatment of this condition.</p>
      </abstract>
      <kwd-group>
        <kwd>Mandible</kwd>
        <kwd>Adenocarcinoma</kwd>
        <kwd>Prostate cancer</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>INTRODUCTION</title>
      <p>Prostate cancer represents the most frequent non-cutaneous neoplasia in males,
corresponding to 40% of the cases, being the second death cause due to malignant tumors
in men. The incidence as much as the mortality increases exponentially after 50 years of
age<sup><xref ref-type="bibr" rid="r05">5</xref>,<xref ref-type="bibr" rid="r09">9</xref>,<xref ref-type="bibr" rid="r10">10</xref></sup>.</p>
      <p>This type of neoplasia can develop peculiar patterns of evolution, presenting, in many
cases, precocious relapse and metastasis. Of a total of patients who have received
curative treatment for the localized prostate cancer, 30% relapse. The most frequent is
the bone metastasis, generally multiple, mainly reaching the vertebral column, shoulder
joints and sacroiliac bone. Among these patients, survival generally varies from 20 to
30 months<sup><xref ref-type="bibr" rid="r05">5</xref>,<xref ref-type="bibr" rid="r10">10</xref></sup>.</p>
      <p>Bone metastasis in the mouth is extremely rare, and represents 1% of all malignant mouth
neoplasias. The incidence is 80 to 90% in the mandible, mainly in the molar region and
it always sign the spreading of the cancer illness. It originates from primary malignant
neoplasias located mainly in the breast, prostate, lung, thyroid and kidney. However,
the occurrence of prostate and kidneys as primary fields for jaw's metastasis through
blood pathways are considered extremely rare<sup><xref ref-type="bibr" rid="r01">1</xref>,<xref ref-type="bibr" rid="r16">16</xref></sup>. Among the bone
metastases affecting the oral cavity, adenocarcinoma is the most frequent histological
type<sup><xref ref-type="bibr" rid="r01">1</xref>,<xref ref-type="bibr" rid="r16">16</xref>,<xref ref-type="bibr" rid="r23">23</xref></sup>.</p>
      <p>The main clinical manifestations may include pain, swelling, tooth loss, bleeding,
trismus, paresthesia sensation (often associated with inferior alveolar nerve
involvement) and epistaxis<sup><xref ref-type="bibr" rid="r19">19</xref></sup>. Included
in the differential diagnosis of metastatic peripheral lesions on the gingiva or
alveolar ridge are pyogenic granuloma, peripheral giant cell granuloma and, possibly,
peripheral ossifying fibroma or ulcerated fibroma<sup><xref ref-type="bibr" rid="r06">6</xref></sup>. The difficulty of clinical identification and differentiation
between primary lesions and metastatic lesions of the jaw make the biopsy with
histopathological analysis (combined with immunohistochemistry) mandatory for
diagnosis<sup><xref ref-type="bibr" rid="r01">1</xref></sup>.</p>
      <p>Besides representing great importance for public health, this issue becomes fundamental
for a multidisciplinary evaluation of the patient.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>Male patient, white, 54 years old, was admitted in the Oral and Maxillofacial Trauma and
Surgery Team at Hospital de Base de Bauru (Bauru Base Hospital), in March 2009. The
patient's main complaint was pain in the left mandibular region above the median line
and paresthesia of the anatomical areas sensitized by the Left Alveolar Inferior Nerve,
branch of the Mandibular Nerve and Trigeminal Nerve. The first signal related by the
patient was a pathology originated from a root treatment about one year before, which
developed a mandibular abscess clinically treated. Once healed from this abscess,
chronic pain persisted in half mandible associated with localized paresthesia. Because
of the posterior absence of dental symptoms even as mandibular pain and face
paresthesia, the clinical dentist referred the patient to the one who suggested the
diagnosis of Trigeminal Neuralgia, establishing treatment with Carbamazepin 200 mg and
Gabapentin 300 mg, both once a day, that lasted about 1 year or more.</p>
      <p>The patient's medical history revealed pharmacologically controlled diabetes and
prostate acinar adenocarcinoma Gleason score 7 (3+4), with initial PSA score on 4.78.
This latter treated in 2005 by means of radical prostatectomy performed in January 2006
(pT3N0M0), having follow-up procedures with urology, but in a random and intermittent
manner, a history not explored or valued by neurology.</p>
      <p>Physical examination revealed left mandibular bulging in the buccolingual aspect and
tooth mobility involving bulging region extending to the opposite canine tooth
associated with a slight gums erythema, but without symptoms compatible with periodontal
disease. In addition, we observed the absence of pathognomonic signs and symptoms of
classic Trigeminal Neuralgia, showing no intermittent pain, neither specific localized
pain spots (trigger-points). Based on this clinical symptomatology, we established a
hypothesis of diagnosis as osteomyelitis and/or cancer, not yet discarding the
possibility of Atypical Neuralgia of the Trigeminal Nerve (<xref ref-type="fig" rid="f01">Figure 1</xref>).</p>
      <fig id="f01" orientation="portrait" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Clinical aspect of the patient. It is possible to see the bulging involving left
buccolingual region of premolars and molars. Source: Oral and Maxillofacial
Surgery team &#x2013; Bauru Base Hospital Association</p>
        </caption>
        <graphic xlink:href="jaos-21-05-0490-g01"/>
      </fig>
      <p>Through a radiography exam, it was possible to define a mild, diffuse radiolucency in
the left mandibular body. The Computed Tomography Scan showed an anatomical structure
alteration with osteolysis areas in the premolars, molars and in the left region of the
chin (<xref ref-type="fig" rid="f02">Figures 2</xref> and <xref ref-type="fig" rid="f03">3</xref>).</p>
      <fig id="f02" orientation="portrait" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Panoramic radiography showing diffuse radiolucent area in the left mandibular body
region. Source: Oral and Maxillofacial Surgery team &#x2013; Bauru Base Hospital
Association</p>
        </caption>
        <graphic xlink:href="jaos-21-05-0490-g02"/>
      </fig>
      <fig id="f03" orientation="portrait" position="float">
        <label>Figure 3</label>
        <caption>
          <p>Computed tomography showing areas of osteolysis in the left mandibular body and
symphysis region. Source: Oral and Maxillofacial Surgery team &#x2013; Bauru Base
Hospital Association</p>
        </caption>
        <graphic xlink:href="jaos-21-05-0490-g03"/>
      </fig>
      <p>Because of that, we carried out an incisional biopsy and culture/antibiogram of
sensitivity of the affected area. The results showed adenocarcinoma (clear cell type)
with necrosis areas and infiltrating bone and soft tissue. The isolated microorganism
was <italic>Staphylococcus aureus</italic>. These findings suggest a metastatic tumor
infected by via hematogenous route. The tumor had no communication between the internal
and external environment, without skin or mucosa fistula, confirmed by whole-body bone
scintigraphy with special interest in the mandibular region, where increased uptake of
the radiocontrast agent was observed, as well as in many areas, such as the right
clavicle and scapula, humerus, ribs, spine, sternum, hip bone and femur (right/left)
(<xref ref-type="fig" rid="f04">Figure 4</xref>).</p>
      <fig id="f04" orientation="portrait" position="float">
        <label>Figure 4</label>
        <caption>
          <p>Whole-body bone scintigraphy, increased uptake of the radiocontrast agent observed
in the mandibular region, right clavicle and scapula, humerus, ribs, spine,
sternum, hip bone and femur (right/left). Source: Oral and Maxillofacial Surgery
team &#x2013; Bauru Base Hospital Association</p>
        </caption>
        <graphic xlink:href="jaos-21-05-0490-g04"/>
      </fig>
      <p>After confirming a definitive diagnosis, the patient was taken to the Oncology Clinic,
where in May 2009 was admitted to the Clinical Oncology Department with a metastatic
bone disease diagnosis (prostate acinar adenocarcinoma) confirmed by three different
methods: bone scintigraphy, incisional biopsy and immunohistochemical analysis of
mandibular lesions. The treatment consisted of the use of goserelin acetate (3.6
mg/month) and bisphosphonate (clodronate, 4 ampoules/month). The patient was evaluated
as having good disease control and good tolerance to treatment for some months, when
disseminated neoplasm and pulmonary involvement led to a lethal outcome, with the
patient's death in less than a year.</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>Prostate cancer is a silent disease; the findings show that the prevalence of
histological malignancy exceeds the clinically manifest disease in approximately eight
times. According to the American Cancer Society, for early cancer detection in
individuals without symptoms, it is recommended the digital rectal exam and PSA dosage
annually for individuals over age 50 or 45 for men belonging to risk groups<sup><xref ref-type="bibr" rid="r18">18</xref></sup>.</p>
      <p>The PSA is a kallikrein family protease, produced by the prostate epithelium, whose
function is to solubilize the sperm after ejaculation. The accepted level as the upper
limit of normal PSA is 4 ng/ml<sup><xref ref-type="bibr" rid="r18">18</xref></sup>. The
PSA has a great clinical utility; it serves for early detection of prostate cancer,
cancer staging, prognostic assessment and therapeutical response control<sup><xref ref-type="bibr" rid="r03">3</xref></sup>.</p>
      <p>In addition to the PSA level in case of established disease, it is necessary to evaluate
the prostate cancer advancement by image exams [transrectal ultrasound, bone
scintigraphy, chest radiography, computed tomography of the abdomen and pelvis, magnetic
nuclear resonance of the abdomen and pelvis, and positron emission tomography (PET)] to
define the appropriate therapeutical strategy. In order to classify neoplastic levels,
some methods are used to analyze the histological grade (Gleason score), tumor volume
and stage at the diagnosis time<sup><xref ref-type="bibr" rid="r12">12</xref>-<xref ref-type="bibr" rid="r14">14</xref>,<xref ref-type="bibr" rid="r16">16</xref></sup>.</p>
      <p>When the primary tumor volume is less than 3 ml, metastasis rarely occurs. When the
present volume is greater than 12 ml metastasis is almost always present<sup><xref ref-type="bibr" rid="r05">5</xref>,<xref ref-type="bibr" rid="r16">16</xref></sup>. According to McNeal<sup><xref ref-type="bibr" rid="r11">11</xref></sup>(1992), only tumors larger than 1 cm in diameter (volume of 0.5 ml)
are capable of extracapsular extension. The lymph nodes or seminal vesicles spread are
usually more common in tumors larger than 2 cm in diameter<sup><xref ref-type="bibr" rid="r11">11</xref></sup>.</p>
      <p>The Gleason system has been introduced to aid on the tumor evolution prediction and the
pathological staging by transrectal biopsy or of the surgical specimen itself. The
lesions with Gleason score 2-4 (well differentiated) have a more indolent behavior,
whereas the ones scoring 7-10 (undifferentiated) are aggressive, responding poorly to
various treatment options<sup><xref ref-type="bibr" rid="r06">6</xref></sup>.</p>
      <p>The clinical staging of tumors, TNM classification, has been adopted to characterize
tumors, helping in choosing the most appropriate therapy and to estimating the patients'
survival chances. This system evaluates the primary tumor, regional lymph nodes and
distant metastases<sup><xref ref-type="bibr" rid="r19">19</xref></sup>.</p>
      <p>The patients' selection for specific treatments is usually done through the risk of
tumor recurrence and dissemination subdivision. Among the therapeutical modalities there
are clinical observation, surgery, radiotherapy, chemotherapy, hormonal therapy and
combination therapy.</p>
      <p>Rutsatz, et al.<sup><xref ref-type="bibr" rid="r17">17</xref></sup> (1990) in a period
of 35 years, reported 1008 patients with craniofacial malignancies, found only five
patients (0.5%) with metastatic tumors to the jaw, from different primary sites. Van der
Waal, et al.<sup><xref ref-type="bibr" rid="r23">23</xref></sup> (2003), identified
adenocarcinoma as the primary histological type responsible for gnathic bone metastases,
starting from different locations of primary tumors, confirming the reported case.</p>
      <p>The four most common tumor sites that metastasize to the man jaws, in descending order
of frequency, are lung, prostate, kidney and liver and, in women, breast, adrenal gland,
female genital organs (uterus, cervix, ovaries) and colorectum. In the first decade of
life, tumors of the adrenal gland (neuroblastoma) most frequently spread to the jaws and
in the second decade, bone primaries prevail (osteosarcoma, Ewing's/PNET)<sup><xref ref-type="bibr" rid="r08">8</xref></sup>. Most patients with oral metastasis,
generally have the primary cancer well diagnosed, confirming the reported case in which
the primary tumor was treated years before by radical prostatectomy and the patient was
still on medical care during the gnathic metastasis. In 25-35% of cases, the presence of
metastasis on the head and neck is the first sign of disseminated malignant disease, and
in about 70% of cases, metastatic lesions are diagnosed in conjunction with the primary
focus. Sometimes, however, the diagnosis of the primary lesion may be difficult or even
impossible<sup><xref ref-type="bibr" rid="r02">2</xref>,<xref ref-type="bibr" rid="r21">21</xref></sup>.</p>
      <p>Multidisciplinary work is recommended in the care of patients with malignant neoplasms
or neurological disorder of doubtful identification in order to provide diagnosis,
planning and treatment that offer the most favorable prognosis.</p>
      <p>Piattelli, et al.<sup><xref ref-type="bibr" rid="r15">15</xref></sup> (1999) conducted a
survey of 390 oral cancer cases, of which 22 cases (5.6%) were metastatic tumors on
gnathic bones from other regions, being prostate gland the primary site of these tumors,
as occurred in our case.</p>
      <p>In cases of metastatic bone illness, the pain and pathological fractures are prevalent
manifestations, although the condition is asymptomatic in some patients. In this case,
the patient reported the presence of chronic pain in hemi mandible, including a
localized paresthesia, symptoms that were initially treated as Trigeminal Neuralgia.
However, by conducting special examinations, we obtained the diagnosis of metastatic
adenocarcinoma prostate cancer in the lung and bone, involving, in addition to the cited
organs, the mandibular region. Bone tumor involvement of the oral region is higher
compared to the soft tissue. Metastatic disease in the jaws may also affect the adjacent
soft tissues and present as dental or periodontal infection<sup><xref ref-type="bibr" rid="r20">20</xref></sup>. When the metastasis is located in the jaw, the primary
neoplasm is more likely to develop bone metastases, especially in the molar
region<sup><xref ref-type="bibr" rid="r01">1</xref></sup>. It is believed that the
greatest amount of cancellous bone present in the region is the reason for the higher
frequency of involvement when compared to other facial bones, as trabecular bone
presents growth factors that improve the neoplasia spread, confirming the reported case
in which bone metastasis reached the region of the body and the mandibular
symphysis<sup><xref ref-type="bibr" rid="r08">8</xref></sup>.</p>
      <p>The unilateral paresthesia type, as occurred in this case, hypoesthesia or anesthesia of
the lower lip, known as Numb Chin Syndrome with or without the presence of pain, may be
the initial clinical manifestation of a significant percentage that manifests on the
jaw. Alterations in sensitivity involving the lower lip, even without significant
radiological changes, should alert the expert to think about the possibility of an
initial metastasis<sup><xref ref-type="bibr" rid="r01">1</xref>,<xref ref-type="bibr" rid="r21">21</xref></sup>. For an accurate diagnosis and treatment of this rare
condition, detailed and careful evaluation of the clinical picture, associated with a
high degree of suspicion, is needed, requiring a multidisciplinary approach to the
case<sup><xref ref-type="bibr" rid="r08">8</xref>,<xref ref-type="bibr" rid="r21">21</xref></sup>.</p>
      <p>The prognosis of these patients is reserved for the pathophysiology of the primary
tumor. Usually, with minimal cellular differentiation they may render the initial site
location. In addition, bone metastases are associated with advanced disease and in some
cases may be involved in malignant lesions - which may lead the patient to death, as
reported in this case<sup><xref ref-type="bibr" rid="r07">7</xref></sup>.</p>
      <p>The radiation treatment can be considered curative regarding single oral metastases
whose primary focus is clearly identified and which responded well to therapy. However,
most authors consider an unfavorable prognosis for most cases of this oral
cancer<sup><xref ref-type="bibr" rid="r02">2</xref></sup>. Surgical treatment in
most cases is not recommended, indicating palliative therapy. The cases that may have a
better indication are those with localized metastases, with no other identified
metastasis and controlled primary disease, which does not occur in our case, since the
examination of bone scintigraphy identified multiple metastatic tumors distributed
throughout the body, palliative therapy being considered the best alternative<sup><xref ref-type="bibr" rid="r14">14</xref></sup>.</p>
      <p>Chemotherapy is indicated only in metastatic disease refractory to hormonal treatment,
as in cases of predominance of hormone-independent cell clones or progressive increase
in serum PSA<sup><xref ref-type="bibr" rid="r22">22</xref></sup>. The use of
bisphosphonates, as reported in the present case, is justified in the presence of bone
metastases and when refractory to hormonal treatment, despite the risk of complications
related to these drugs, such as osteonecrosis. There is an interesting indication to the
use of these drugs as this therapy provides control of the neoplastic disease and also a
relative patient survival chance<sup><xref ref-type="bibr" rid="r04">4</xref></sup>. In
advanced cases, the quality of life, despite the patients having no chance of cure for
the disease, is the main objective, providing less pain and discomfort<sup><xref ref-type="bibr" rid="r17">17</xref></sup>.</p>
    </sec>
    <sec>
      <title>FINAL CONSIDERATIONS</title>
      <p>Metastatic lesions are related to the advanced stage of the disease and usually with a
high degree of histological aggressiveness. This fact explains the difficulty of
curative treatment, and these injuries are usually classified as reserved and dark
prognosis. It is important to emphasize the relevance of detailed clinical examination
and multidisciplinary evaluation in order to establish the differential diagnosis and so
the correct treatment.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Amonett</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>McGinnis</surname>
              <given-names>JP</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Krolls</surname>
              <given-names>SO</given-names>
            </name>
          </person-group>
          <article-title>Metastasis to the mandible</article-title>
          <source>Miss Dent Assoc J</source>
          <year>1998</year>
          <volume>54</volume>
          <issue>2</issue>
          <fpage>36</fpage>
          <lpage>39</lpage>
          <pub-id pub-id-type="pmid">9800563</pub-id>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Antunes</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Antunes</surname>
              <given-names>AP</given-names>
            </name>
          </person-group>
          <article-title>Gnathic bone metastasis: a retrospective study of 10
cases</article-title>
          <source>Rev Bras Otorrinolaringol</source>
          <year>2008</year>
          <volume>74</volume>
          <issue>4</issue>
          <fpage>561</fpage>
          <lpage>565</lpage>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bill-Axelson</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Holmberg</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ruutu</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Garmo</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Stark</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Busch</surname>
              <given-names>C</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Radical prostatectomy versus watchful waiting in early prostate
cancer</article-title>
          <source>N Engl J Med</source>
          <year>2011</year>
          <volume>364</volume>
          <issue>18</issue>
          <fpage>1708</fpage>
          <lpage>1717</lpage>
          <pub-id pub-id-type="pmid">21542742</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Catalona</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Antenor</surname>
              <given-names>JAV</given-names>
            </name>
            <name>
              <surname>Roehl</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Moul</surname>
              <given-names>JW</given-names>
            </name>
          </person-group>
          <article-title>Screening for prostate cancer in high risk populations</article-title>
          <source>J Urol</source>
          <year>2002</year>
          <volume>186</volume>
          <fpage>1980</fpage>
          <lpage>1984</lpage>
          <pub-id pub-id-type="pmid">12394689</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Clarke</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Boyette</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Vural</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Suen</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Anaissie</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Stack</surname>
              <given-names>BC</given-names>
              <suffix>Jr</suffix>
            </name>
          </person-group>
          <article-title>Bisphosphonates and jaw osteonecrosis: the UAMS
experience</article-title>
          <source>Otolaryngol Head Neck Surg</source>
          <year>2007</year>
          <volume>136</volume>
          <issue>3</issue>
          <fpage>396</fpage>
          <lpage>400</lpage>
          <pub-id pub-id-type="pmid">17321866</pub-id>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>D'Silva</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Summerlin</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Cordell</surname>
              <given-names>KG</given-names>
            </name>
            <name>
              <surname>Abdelsayed</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Tomich</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Hanks</surname>
              <given-names>CT</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Metastatic tumors in the jaws: a retrospective study of 114
cases</article-title>
          <source>J Am Dent Assoc</source>
          <year>2006</year>
          <volume>137</volume>
          <fpage>1667</fpage>
          <lpage>1672</lpage>
          <pub-id pub-id-type="pmid">17138711</pub-id>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Harrison</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Lund</surname>
              <given-names>VJ</given-names>
            </name>
          </person-group>
          <source>Tumors of the upper jaw</source>
          <publisher-loc>New York</publisher-loc>
          <publisher-name>Churchil Livingstone</publisher-name>
          <year>1993</year>
        </element-citation>
      </ref>
      <ref id="r08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hirshberg</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Shnaiderman-Shapiro</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kaplan</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Berger</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Metastatic tumours to the oral cavity - pathogenesis and analysis of
673 cases</article-title>
          <source>Oral Oncol</source>
          <year>2008</year>
          <volume>44</volume>
          <fpage>743</fpage>
          <lpage>752</lpage>
          <pub-id pub-id-type="pmid">18061527</pub-id>
        </element-citation>
      </ref>
      <ref id="r09">
        <label>9</label>
        <element-citation publication-type="book">
          <source>INCA - National Cancer Institute of Brazil [database]</source>
          <publisher-loc>Rio de Janeiro</publisher-loc>
          <publisher-name>Ministry of Health, Federal Government - Brasil</publisher-name>
          <date-in-citation content-type="access-date">cited 2009 Sep 01</date-in-citation>
          <comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.inca.gov.br/conteudo_view.asp?id=339">http://www.inca.gov.br/conteudo_view.asp?id=339</ext-link></comment>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jemal</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Thun</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Cancer statistics, 2002</article-title>
          <source>CA Cancer J Clin</source>
          <year>2002</year>
          <volume>52</volume>
          <fpage>23</fpage>
          <lpage>47</lpage>
          <pub-id pub-id-type="pmid">11814064</pub-id>
        </element-citation>
      </ref>
      <ref id="r11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McNeal</surname>
              <given-names>JE</given-names>
            </name>
          </person-group>
          <article-title>Cancer volume and site of origin of adenocarcinoma of the prostate:
relationship to local and distant spread</article-title>
          <source>Hum Pathol</source>
          <year>1992</year>
          <volume>23</volume>
          <fpage>258</fpage>
          <lpage>266</lpage>
          <pub-id pub-id-type="pmid">1555836</pub-id>
        </element-citation>
      </ref>
      <ref id="r12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Memon</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Jaleel</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Aftab</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Pattern of prostatic carcinoma metastases in bones detected by bone
scans using Technitium 99m Methyl Diphosphate (TC99m MDP) imaging
technique</article-title>
          <source>Pak J Med Sci</source>
          <year>2006</year>
          <volume>22</volume>
          <issue>2</issue>
          <fpage>180</fpage>
          <lpage>183</lpage>
        </element-citation>
      </ref>
      <ref id="r13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Narayan</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Gajendran</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Tewari</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Presti</surname>
              <given-names>JC</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Leidich</surname>
              <given-names>R</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>The role of transrectal ultrasound-guided biopsy-based staging,
preoperative serum prostate-specific antigen, and biopsy Gleason score in
prediction of final pathologic diagnosis in prostate cancer</article-title>
          <source>Urology</source>
          <year>1995</year>
          <volume>46</volume>
          <fpage>205</fpage>
          <lpage>212</lpage>
          <pub-id pub-id-type="pmid">7542823</pub-id>
        </element-citation>
      </ref>
      <ref id="r14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Partin</surname>
              <given-names>AW</given-names>
            </name>
            <name>
              <surname>Kattan</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Subong</surname>
              <given-names>EN</given-names>
            </name>
            <name>
              <surname>Walsh</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Wojno</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Oesterling</surname>
              <given-names>JE</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Combination of prostate-specific antigen, clinical stage, and Gleason
score to predict pathological stage of localized prostate cancer. A
multi-institutional update</article-title>
          <source>JAMA</source>
          <year>1997</year>
          <volume>277</volume>
          <fpage>1445</fpage>
          <lpage>1451</lpage>
          <pub-id pub-id-type="pmid">9145716</pub-id>
        </element-citation>
      </ref>
      <ref id="r15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Piattelli</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Fioroni</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rubini</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Gingival metastasis from a prostate adenocarcinoma: report of a
case</article-title>
          <source>J Periodontol</source>
          <year>1999</year>
          <volume>70</volume>
          <issue>4</issue>
          <fpage>441</fpage>
          <lpage>444</lpage>
          <pub-id pub-id-type="pmid">10328657</pub-id>
        </element-citation>
      </ref>
      <ref id="r16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pruckmayer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Glaser</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Marosi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Leitha</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Mandibular pain as the leading clinical symptom for metastatic
disease: nine cases and review of the literature</article-title>
          <source>Ann Oncol</source>
          <year>1998</year>
          <volume>9</volume>
          <issue>5</issue>
          <fpage>559</fpage>
          <lpage>564</lpage>
          <pub-id pub-id-type="pmid">9653498</pub-id>
        </element-citation>
      </ref>
      <ref id="r17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sandler</surname>
              <given-names>HM</given-names>
            </name>
            <name>
              <surname>Eisenberger</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Assessing and treating patients with increasing prostate specific
antigen following radical prostatectomy</article-title>
          <source>J Urol</source>
          <year>2007</year>
          <volume>178</volume>
          <issue>3</issue>
          <fpage>S20</fpage>
          <lpage>S24</lpage>
          <pub-id pub-id-type="pmid">17644123</pub-id>
        </element-citation>
      </ref>
      <ref id="r18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Smith</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Cokkinides</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Eyre</surname>
              <given-names>HJ</given-names>
            </name>
          </person-group>
          <article-title>American Cancer Society guidelines for the early detection of cancer,
2006</article-title>
          <source>CA Cancer J Clin</source>
          <year>2006</year>
          <volume>56</volume>
          <fpage>11</fpage>
          <lpage>25</lpage>
          <pub-id pub-id-type="pmid">16449183</pub-id>
        </element-citation>
      </ref>
      <ref id="r19">
        <label>19</label>
        <element-citation publication-type="book">
          <person-group person-group-type="editor">
            <name>
              <surname>Sobin</surname>
              <given-names>LH</given-names>
            </name>
            <name>
              <surname>Wittekind</surname>
              <given-names>Ch</given-names>
            </name>
          </person-group>
          <source>TNM classification of malignant tumours</source>
          <edition>6th ed</edition>
          <publisher-loc>New York</publisher-loc>
          <publisher-name>Wiley-Liss</publisher-name>
          <year>2002</year>
        </element-citation>
      </ref>
      <ref id="r20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stege</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Potential side-effects of endocrine treatment of long duration in
prostate cancer</article-title>
          <source>Prostate Suppl</source>
          <year>2000</year>
          <volume>10</volume>
          <fpage>38</fpage>
          <lpage>42</lpage>
          <pub-id pub-id-type="pmid">11056492</pub-id>
        </element-citation>
      </ref>
      <ref id="r21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tamiolakis</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Tsamis</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Thomaidis</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Lambropoulou</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Alexiadis</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Venizelos</surname>
              <given-names>I</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Jaw bone metastases: four cases</article-title>
          <source>Acta Dermatovenerol Alp Panonica Adriat</source>
          <year>2007</year>
          <volume>16</volume>
          <issue>1</issue>
          <fpage>21</fpage>
          <lpage>25</lpage>
          <pub-id pub-id-type="pmid">17992450</pub-id>
        </element-citation>
      </ref>
      <ref id="r22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tannock</surname>
              <given-names>IF</given-names>
            </name>
            <name>
              <surname>de Wit</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Berry</surname>
              <given-names>WR</given-names>
            </name>
            <name>
              <surname>Horti</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Pluzanska</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Chi</surname>
              <given-names>KN</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced
prostate cancer</article-title>
          <source>N Engl J Med</source>
          <year>2004</year>
          <volume>351</volume>
          <issue>15</issue>
          <fpage>1502</fpage>
          <lpage>1512</lpage>
          <pub-id pub-id-type="pmid">15470213</pub-id>
        </element-citation>
      </ref>
      <ref id="r23">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Van der Waal</surname>
              <given-names>RI</given-names>
            </name>
            <name>
              <surname>Buter</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Van der Waal</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Oral metastases: report of 24 cases</article-title>
          <source>Br J Oral Maxillofac Surg</source>
          <year>2003</year>
          <volume>4</volume>
          <issue>1</issue>
          <fpage>3</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="pmid">12576032</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
